Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma plc (~292)

  Print      Mail a friend       Annual reports

Monday 29 March, 2010

Antisoma plc

ATTRACT-1 phase III trial of ASA404 halted foll...

29 March 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:
ATSMY) announces that the planned interim analysis of data from the ATTRACT-1
phase III trial of ASA404 in previously untreated non-small cell lung cancer
(NSCLC) has shown that continuation of the trial would be futile, as there is
little or no prospect of demonstrating a survival benefit with ASA404 in this
setting. The ATTRACT-1 trial will therefore be halted.

No new or unexpected serious adverse effects of ASA404 have been identified by
the trial's Data Monitoring Committee.

Glyn Edwards, CEO of Antisoma, said: "We are disappointed by the outcome of the
ATTRACT-1 study, especially given the very encouraging phase II data reported in
the same setting. We had hoped that this trial would show that use of ASA404
could improve treatment for patients with newly diagnosed lung cancer. We are
now focused on delivering phase III results for our other late-stage product,

Antisoma had unaudited cash and short-term investments of GBP 45.1 million at
the end of February 2010.

A conference call will be held today at 9 am UK time. This will be available
afterwards as a recording on the Antisoma website
<>. A further conference call will be held at 2 pm UK
time/9 am Eastern time. Dial-in numbers for the calls are as follows: + 44 (0)20
3364 5947; UK Toll Free: 0808 238 7396; US Toll Free: 1866 793 4273; participant
pin code: 468563#

  Glyn Edwards, CEO
  Daniel Elger, VP Marketing & Communications   +44 (0)7909 915 068
  Antisoma plc

  Mark Court/Lisa Baderoon/Catherine Breen      +44 (0)20 7466 5000
  Buchanan Communications

  Seth Lewis                                    +1 617 583 1308
  The Trout Group

Except for the historical information presented, certain matters discussed in
this announcement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.

About the ATTRACT-1 study in NSCLC
ATTRACT-1 was a pivotal study of ASA404 in previously untreated, advanced NSCLC.
Patients were randomised 1:1 to receive either ASA404 plus chemotherapy
(carboplatin/paclitaxel) or a placebo plus chemotherapy (carboplatin/paclitaxel)
as a control.

About ASA404
ASA404 (vadimezan, formerly known as DMXAA and AS1404) is a small-molecule
Tumour-Vascular Disrupting Agent (Tumour-VDA) which targets the blood vessels
that nourish tumours. The drug wasdiscovered by Professors Bruce Baguley and
William Denny and their teams at the Auckland Cancer Society Research Centre,
University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer
Research Ventures Limited (now Cancer Research Technology), the development and
commercialisation company of the Cancer Research Campaign (now Cancer Research
UK), in 2001. Worldwide rights to the drug were licensed to Novartis AG in April

About Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. In addition to ASA404, the
Company's drugs in development include AS1413, being tested in a phase III trial
as a treatment for secondary acute myeloid leukaemia (AML), AS1411, being tested
in a phase IIb trial in AML, and a pre-clinical programme of Dendritic Cell
Autoimmune Modulators (DCAMs), being developed for auto-immune indications. The
Company has operations in the UK and the US. Please
<> for further information about Antisoma.

- END -




a d v e r t i s e m e n t